HIV, CONFERMATA ELEVATA PERSISTENZA DI TERAPIE E PREP ‘LONG ACTING’
Dagli Usa in occasione del Croi giunge la conferma della elevata persistenza di terapie e PrEP “long acting”: un’iniezione ogni due mesi può essere sufficiente La somministrazione dei farmaci long…
Semaglutide Reduces Severity of Common Liver Disease in People with HIV #CROI2024
A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according…
Tools underestimate cardiovascular event risk in people with HIV #CROI2024
The elevated cardiovascular disease risk among people with HIV is even greater than predicted by a standard risk calculator in several groups, including Black people and cisgender women, according to…